Table 4 |.
Main attributes of clinically relevant nanotheranostics.
| Nanotheranostic | size (nm) |
composition | blood longeivty | route of Administration | First Trial | Major Application |
|---|---|---|---|---|---|---|
| ferumoxides 64 | 50 – 100 | dextran-coated IONP | < 1 h | iv/local | 09/1999 | liver imaging |
| ferumoxytol 66 | 17 – 31 | polyglucose sorbitol carboxymethylether - coated IONP | ~ 15 h | iv/local | 05/2004 | anemia treatment |
| AuroShell 58 | 150 | Au nanoshell on a silica core | 3 – 6 h | iv | 04/2008 | cancer ablation |
| 64Cu-MM-302 107 | ~ 100 | 64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin | ~ 33 h | iv | 03/2011 | cancer chemotherapy |
| Carbon NP 83 | ~ 10 | carbon pellet (after surface modification ~ 150) | - | local | 01/2012 | lymph node dissection |
| NBTXR3 78 | 50 | functionalized hafnium oxide nanoparticles | - | local | 01/2014 | head & neck cancer |
| Cornell Dots 80 | ~ 10 | radiolabeled molecular targeted PEGylated silica matrix | - | iv/local | 04/2014 | lymph node dissection |
| 188Re-Liposome 109 | ~ 80 | 188Re-labeled PEGylated liposome | ~ 40 h | iv | 10/2014 | terminated |
| AGuIX 77 | ~ 5 | Gd chelated-polysiloxane | > 6h | iv | 03/2016 | cancer radiotherapy |
| 89Zr-CPC634 108 | 65 | radiolabeled docetaxel-loaded nanoparticles | ~ 60 h | iv | 04/2018 | cancer chemotherapy |
IONP: iron oxide nanoparticle; AGuIX: polymeric gadolinium complexes; AuroShell: silica gold nanoshells; NBTXR3: hafnium oxide nanoparticles; Carbon NP: carbon nanoparticle; 89Zr-CPC634: 89Zr-labeled polymeric nanoparticles carrying docetaxel; 64Cu-MM-302: 64Cu-labeled liposomes carrying doxorubicin; 188Re-liposome: 188Re-labeled liposome; iv: intravenous administration.